NASDAQ:AVROAvrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 3.4% and is now trading at $17.41. View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) announced its earnings results on Thursday, May, 7th. The company reported ($0.77) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.66) by $0.11. View Avrobio's earnings history.

7 Wall Street analysts have issued 12 month target prices for Avrobio's shares. Their forecasts range from $13.00 to $43.00. On average, they anticipate Avrobio's stock price to reach $33.60 in the next twelve months. This suggests a possible upside of 93.0% from the stock's current price. View analysts' price targets for Avrobio.

Media coverage about AVRO stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Avrobio earned a coverage optimism score of -2.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about Avrobio.

Avrobio saw a increase in short interest in June. As of June 30th, there was short interest totaling 1,960,000 shares, an increase of 13.3% from the June 15th total of 1,730,000 shares. Based on an average daily volume of 341,000 shares, the days-to-cover ratio is presently 5.7 days. Currently, 6.7% of the shares of the company are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Twist Bioscience (TWST), Immunovant (IMVT), Alector (ALEC), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Adverum Biotechnologies (ADVM), Bill.com (RVMD), Sorrento Therapeutics (SRNE), Mesoblast (MESO), Sangamo Therapeutics (SGMO), Beam Therapeutics (BEAM), Regenxbio (RGNX), Nantkwest (NK), Legend Biotech (PCVX) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE).

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $17.41.

Avrobio has a market capitalization of $627.37 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

The official website for Avrobio is www.avrobio.com.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]